Which has higher earnings and valuation, VRCI or GDR?

Verici Dx has higher revenue and earnings than genedrive. genedrive is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verici Dx £3.66M 1.37 -£6.56M -£0.90 N/A genedrive £929K 23.57 -£21.22M -£0.79 N/A

Is VRCI or GDR more profitable?

Verici Dx has a net margin of -193.05% compared to genedrive's net margin of -500.75%. Verici Dx's return on equity of -138.93% beat genedrive's return on equity. Company Net Margins Return on Equity Return on Assets Verici Dx -193.05% -138.93% -26.14% genedrive -500.75% -1,044.57% -74.09%

Is VRCI or YGEN more profitable?

Yourgene Health has a net margin of -27.55% compared to Verici Dx's net margin of -193.05%. Yourgene Health's return on equity of -27.06% beat Verici Dx's return on equity. Company Net Margins Return on Equity Return on Assets Verici Dx -193.05% -138.93% -26.14% Yourgene Health -27.55% -27.06% -6.71%

Which has preferable earnings & valuation, VRCI or AGL?

Verici Dx has higher revenue and earnings than ANGLE. ANGLE is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verici Dx £3.66M 1.37 -£6.56M -£0.90 N/A ANGLE £2.62M 2.89 -£21.76M -£4.80 N/A

Is VRCI or AGL more profitable?

Verici Dx has a net margin of -193.05% compared to ANGLE's net margin of -1,444.04%. Verici Dx's return on equity of -138.93% beat ANGLE's return on equity. Company Net Margins Return on Equity Return on Assets Verici Dx -193.05% -138.93% -26.14% ANGLE -1,444.04% -191.36% -29.89%

Is GENI or VRCI more profitable?

GENinCode has a net margin of -185.47% compared to Verici Dx's net margin of -193.05%. Verici Dx's return on equity of -138.93% beat GENinCode's return on equity. Company Net Margins Return on Equity Return on Assets GENinCode -185.47% -409.40% -63.99% Verici Dx -193.05% -138.93% -26.14%

Is PRM or VRCI more profitable?

Proteome Sciences has a net margin of -81.50% compared to Verici Dx's net margin of -193.05%. Proteome Sciences' return on equity of 33.80% beat Verici Dx's return on equity. Company Net Margins Return on Equity Return on Assets Proteome Sciences -81.50% 33.80% -19.25% Verici Dx -193.05% -138.93% -26.14%

Verici Dx (VRCI) Competitors

GBX 0.22 -0.01 (-2.67%)

As of 10:09 AM Eastern

Compare

VRCI vs. GDR, YGEN, AGL, GENI, and PRM

Should you buy Verici Dx stock or one of its competitors? Verici Dx's main competitors and comparable companies include genedrive (GDR), Yourgene Health (YGEN), ANGLE (AGL), GENinCode (GENI), and Proteome Sciences (PRM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Verici Dx compare to genedrive?

Verici Dx (LON:VRCI) and genedrive (LON:GDR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Verici Dx has a beta of 1.256, meaning that its stock price is 26% more volatile than the broader market. Comparatively, genedrive has a beta of 0.989, meaning that its stock price is 1% less volatile than the broader market.

In the previous week, genedrive had 1 more articles in the media than Verici Dx. MarketBeat recorded 1 mentions for genedrive and 0 mentions for Verici Dx. genedrive's average media sentiment score of 0.68 beat Verici Dx's score of 0.00 indicating that genedrive is being referred to more favorably in the news media.

Company	Overall Sentiment
Verici Dx	Neutral
genedrive	Positive

15.7% of Verici Dx shares are owned by institutional investors. Comparatively, 0.1% of genedrive shares are owned by institutional investors. 1.2% of Verici Dx shares are owned by company insiders. Comparatively, 29.0% of genedrive shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Verici Dx has a net margin of -193.05% compared to genedrive's net margin of -500.75%. Verici Dx's return on equity of -138.93% beat genedrive's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verici Dx	-193.05%	-138.93%	-26.14%
genedrive	-500.75%	-1,044.57%	-74.09%

Verici Dx has higher revenue and earnings than genedrive. genedrive is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verici Dx	£3.66M	1.37	-£6.56M	-£0.90	N/A
genedrive	£929K	23.57	-£21.22M	-£0.79	N/A

Summary

Verici Dx beats genedrive on 8 of the 13 factors compared between the two stocks.

How does Verici Dx compare to Yourgene Health?

Verici Dx (LON:VRCI) and Yourgene Health (LON:YGEN) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

Verici Dx has higher earnings, but lower revenue than Yourgene Health. Verici Dx is trading at a lower price-to-earnings ratio than Yourgene Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verici Dx	£3.66M	1.37	-£6.56M	-£0.90	N/A
Yourgene Health	£29.67M	0.00	-£8.17M	-£0.01	N/A

In the previous week, Verici Dx's average media sentiment score of 0.00 equaled Yourgene Health'saverage media sentiment score.

Company	Overall Sentiment
Verici Dx	Neutral
Yourgene Health	Neutral

Verici Dx has a beta of 1.256, indicating that its stock price is 26% more volatile than the broader market. Comparatively, Yourgene Health has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

15.7% of Verici Dx shares are held by institutional investors. Comparatively, 23.3% of Yourgene Health shares are held by institutional investors. 1.2% of Verici Dx shares are held by insiders. Comparatively, 64.4% of Yourgene Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Yourgene Health has a net margin of -27.55% compared to Verici Dx's net margin of -193.05%. Yourgene Health's return on equity of -27.06% beat Verici Dx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verici Dx	-193.05%	-138.93%	-26.14%
Yourgene Health	-27.55%	-27.06%	-6.71%

Summary

Yourgene Health beats Verici Dx on 7 of the 10 factors compared between the two stocks.

How does Verici Dx compare to ANGLE?

Verici Dx (LON:VRCI) and ANGLE (LON:AGL) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

In the previous week, ANGLE had 1 more articles in the media than Verici Dx. MarketBeat recorded 1 mentions for ANGLE and 0 mentions for Verici Dx. Verici Dx's average media sentiment score of 0.00 equaled ANGLE'saverage media sentiment score.

Company	Overall Sentiment
Verici Dx	Neutral
ANGLE	Neutral

15.7% of Verici Dx shares are held by institutional investors. Comparatively, 17.5% of ANGLE shares are held by institutional investors. 1.2% of Verici Dx shares are held by insiders. Comparatively, 2.7% of ANGLE shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Verici Dx has a net margin of -193.05% compared to ANGLE's net margin of -1,444.04%. Verici Dx's return on equity of -138.93% beat ANGLE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verici Dx	-193.05%	-138.93%	-26.14%
ANGLE	-1,444.04%	-191.36%	-29.89%

Verici Dx has a beta of 1.256, indicating that its stock price is 26% more volatile than the broader market. Comparatively, ANGLE has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market.

Verici Dx has higher revenue and earnings than ANGLE. ANGLE is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verici Dx	£3.66M	1.37	-£6.56M	-£0.90	N/A
ANGLE	£2.62M	2.89	-£21.76M	-£4.80	N/A

Summary

Verici Dx beats ANGLE on 8 of the 12 factors compared between the two stocks.

How does Verici Dx compare to GENinCode?

GENinCode (LON:GENI) and Verici Dx (LON:VRCI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

11.4% of GENinCode shares are owned by institutional investors. Comparatively, 15.7% of Verici Dx shares are owned by institutional investors. 8.4% of GENinCode shares are owned by insiders. Comparatively, 1.2% of Verici Dx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

GENinCode has a beta of 0.557, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Verici Dx has a beta of 1.256, indicating that its stock price is 26% more volatile than the broader market.

In the previous week, GENinCode's average media sentiment score of 0.00 equaled Verici Dx'saverage media sentiment score.

Company	Overall Sentiment
GENinCode	Neutral
Verici Dx	Neutral

GENinCode has higher earnings, but lower revenue than Verici Dx. GENinCode is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GENinCode	£3.08M	2.09	-£6.10M	-£2.08	N/A
Verici Dx	£3.66M	1.37	-£6.56M	-£0.90	N/A

GENinCode has a net margin of -185.47% compared to Verici Dx's net margin of -193.05%. Verici Dx's return on equity of -138.93% beat GENinCode's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GENinCode	-185.47%	-409.40%	-63.99%
Verici Dx	-193.05%	-138.93%	-26.14%

Summary

Verici Dx beats GENinCode on 7 of the 11 factors compared between the two stocks.

How does Verici Dx compare to Proteome Sciences?

Proteome Sciences (LON:PRM) and Verici Dx (LON:VRCI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

In the previous week, Proteome Sciences had 1 more articles in the media than Verici Dx. MarketBeat recorded 1 mentions for Proteome Sciences and 0 mentions for Verici Dx. Proteome Sciences' average media sentiment score of 0.00 equaled Verici Dx'saverage media sentiment score.

Company	Overall Sentiment
Proteome Sciences	Neutral
Verici Dx	Neutral

Proteome Sciences has a beta of 0.148, suggesting that its share price is 85% less volatile than the broader market. Comparatively, Verici Dx has a beta of 1.256, suggesting that its share price is 26% more volatile than the broader market.

Proteome Sciences has higher revenue and earnings than Verici Dx. Proteome Sciences is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Proteome Sciences	£3.76M	1.73	-£4.08M	-£1.04	N/A
Verici Dx	£3.66M	1.37	-£6.56M	-£0.90	N/A

Proteome Sciences has a net margin of -81.50% compared to Verici Dx's net margin of -193.05%. Proteome Sciences' return on equity of 33.80% beat Verici Dx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Proteome Sciences	-81.50%	33.80%	-19.25%
Verici Dx	-193.05%	-138.93%	-26.14%

0.0% of Proteome Sciences shares are held by institutional investors. Comparatively, 15.7% of Verici Dx shares are held by institutional investors. 36.7% of Proteome Sciences shares are held by company insiders. Comparatively, 1.2% of Verici Dx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Proteome Sciences beats Verici Dx on 8 of the 12 factors compared between the two stocks.

Get Verici Dx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRCI vs. The Competition

Export

Metric	Verici Dx	Life Sciences Tools & Services Industry	Healthcare Sector	LON Exchange
Market Cap	£5.01M	£10.21B	£7.40B	£2.92B
Dividend Yield	N/A	1.46%	2.53%	6.17%
P/E Ratio	-0.24	63.20	272.19	367.32
Price / Sales	1.37	111.26	631.76	83,741.35
Price / Cash	1.31	27.09	79.89	27.89
Price / Book	0.05	37.51	13.14	7.02
Net Income	-£6.56M	£56.67B	£3.47B	£5.89B
7 Day Performance	0.46%	2.12%	1.38%	0.89%
1 Month Performance	-27.00%	10.71%	8.62%	3.27%
1 Year Performance	-56.20%	25.70%	25.90%	22.28%

Verici Dx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRCI Verici Dx	N/A	GBX 0.22 -2.7%	N/A	-58.8%	£5.01M	£3.66M	N/A	19	Gap Up
GDR genedrive	N/A	GBX 1.35 +1.7%	N/A	+59.1%	£21.72M	£929K	N/A	43	Positive News Gap Up
YGEN Yourgene Health	N/A	N/A	N/A	N/A	£16.43M	£29.67M	N/A	253
AGL ANGLE	N/A	GBX 2.35 -11.3%	N/A	-63.8%	£7.58M	£2.62M	N/A	650	Gap Up
GENI GENinCode	N/A	GBX 0.89 -1.2%	N/A	-36.8%	£6.70M	£3.08M	N/A	2,300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:VRCI) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Verici Dx (VRCI) Competitors